Standard Biotools earnings release, August 5, 2026

Standard Biotools Inc. (LAB) · Form 8-K, Item 2.02 · Filed · SEC filing

Standard BioTools Reports Second Quarter 2026 Financial Results

BOSTON, Mass., August 5, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026.

Recent Highlights:

• Second quarter 2026 revenue of $20.1 million

• 1% improvement in operating loss and 84% improvement in adjusted EBITDA year-over-year

• Merger with Treeline Biosciences progressing toward stockholder vote and anticipated to close before year-end 2026

“We remain on track to close our merger with Treeline Biosciences in 2026, with our previously filed registration statement on Form S-4, our agreement to divest our Mass Cytometry business, and Illumina’s early buyout of contingent payments for $30 million from its acquisition of SomaLogic,” said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. “We continue to believe this merger is the best path forward to maximize shareholder value, providing exposure to a catalyst-rich, well-capitalized pipeline of potential new therapeutics with significant near and long term value creation opportunities, and we look forward to updating stockholders as we progress toward the vote and closing.”

Dr. Egholm continued, “While the transaction process continues, our team remains focused on serving our customers. Our continued cost discipline drove an 84% year-over-year improvement in adjusted EBITDA for the second quarter.”

Financial Results Table: Continuing Operations

Second Quarter 2026 Financial Results:

• Revenue was $20.1 million in the second quarter of 2026, down 7.6% year-over-year.

• Consumables revenue was $9.4 million in the second quarter of 2026, down 10% year-over-year, compared against particularly strong prior year results and continued US Academia spend uncertainty.

• Instruments revenue was $5.1 million in the second quarter of 2026, down 2% year-over-year. Instrument revenue in the quarter remained impacted by capital-constrained end-markets.

• Services revenue, which is predominantly Field Services, was $5.6 million in the second quarter of 2026, down 8% year-over-year.

• Gross margins in the second quarter of 2026 were approximately 52.4%, versus 48.8% in the second quarter of 2025; and non-GAAP gross margins in the second quarter of 2026 were approximately 56.3%, versus 54.1% in the second quarter of 2025. Gross margins and non-GAAP gross margins were driven by productivity improvements and reduced warranty expense.

• Operating expenses in the second quarter of 2026 were $35.9 million, a decrease of $0.4 million, or down 1%, compared to the second quarter of 2025. Operating expenses included $14.7 million in transaction costs and $2.8 million in restructuring and related charges. Non-GAAP operating expenses, which exclude transaction costs, stock-based compensation, and restructuring charges, were $13.8 million in the second quarter of 2026, a decrease of $14.1 million, or down 50%, compared to the second quarter of 2025. The decrease in operating expenses was largely due to previously announced restructuring actions.

• Net loss for the second quarter of 2026 was $21.5 million from continuing operations, compared to a net loss of $17.7 million in the second quarter of 2025, representing a change of $3.8 million or 21%. This was impacted by one-time transaction costs. Adjusted EBITDA for the second quarter of 2026 was a loss of $2.5 million, versus an adjusted EBITDA loss of $16.1 million in the second quarter of 2025, an improvement of $13.6 million, or 84%.

Full Year 2026 Revenue Outlook

Standard BioTools is withdrawing its full year 2026 revenue outlook given the pending merger with Treeline Biosciences.

Use of Non-GAAP Financial Information

Standard BioTools has presented certain financial information in accordance with U.S. GAAP and on a non-GAAP basis. The non-GAAP financial measures included in this press release are non-GAAP gross margin, non-GAAP gross profit, non-GAAP operating expenses, and adjusted EBITDA. Management uses these non-GAAP financial measures, in addition to GAAP financial measures, as a measure of operating performance because the non-GAAP financial measures do not include the impact of items that management does not consider indicative of the Company’s core operating performance. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the Company’s core operating results. Management uses non-GAAP measures to compare the Company’s performance relative to forecasts and strategic plans and to benchmark the Company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the Company’s operating results as reported under U.S. GAAP. Standard BioTools encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP financial measures are presented in the accompanying tables of this release.

Financial statements

Income Statement

Three Months Ended June 30, — Financial Results Table: Continuing Operations (Unaudited, in millions, except percentages)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenue20.121.841.342
Gross margin52.4%48.8%53.0%51.6%
Non-GAAP gross margin56.3%54.1%57.0%55.6%
Operating expenses35.936.359.774.3
Non-GAAP operating expenses13.827.929.153.5
Operating loss-25.4-25.7-37.9-52.7
Net loss from continuing operations-21.5-17.7-36.2-41
Adjusted EBITDA-2.5-16.1-5.6-30.2
Cash, cash equivalents, restricted cash, short-term and long-term investments541.1227.9541.1227.9

Income Statement

Three Months Ended June 30, — (Unaudited) (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Revenue:Product revenue14,51515,67329,96930,454
Revenue:Services and other revenue5,5896,08911,28111,530
Revenue:Total revenue20,10421,76241,25041,984
Cost of revenue:Cost of product revenue6,7977,60814,50314,039
Cost of revenue:Cost of services and other revenue2,7723,5264,9046,268
Cost of revenue:Total cost of revenue9,56911,13419,40720,307
Cost of revenue:Gross profit10,53510,62821,84321,677
Operating expenses:Research and development1,9766,2224,09311,662
Operating expenses:Selling, general and administrative16,38828,10534,99557,929
Operating expenses:Restructuring and related charges2,8121,7275,8923,279
Operating expenses:Transaction and integration expenses14,74727114,7471,474
Operating expenses:Total operating expenses35,92336,32559,72774,344
Operating expenses:Loss from operations-25,388-25,697-37,884-52,667
Operating expenses:Interest income, net4,6112,4528,1225,366
Operating expenses:Other (expense) income, net-6584,963-6,2885,530
Operating expenses:Loss before income taxes-21,435-18,282-36,050-41,771
Operating expenses:Income tax (expense) benefit-90609-101728
Operating expenses:Net loss from continuing operations-21,525-17,673-36,151-41,043
Discontinued operations:(Loss) income from discontinued operations, net of tax-5,233-15,786136,461-18,449
Discontinued operations:Net (loss) income-26,758-33,459100,310-59,492
Discontinued operations:Net loss per share from continuing operations-0.06-0.05-0.09-0.11
Discontinued operations:Net income (loss) per share from discontinued operations-0.01-0.040.35-0.05
Discontinued operations:Net income (loss) per share-0.07-0.090.26-0.16
Discontinued operations:Shares used in computing net loss per share attributable to common stockholders, basic and diluted390,881380,498389,549379,369

Income Statement

Three Months Ended June 30, — (Unaudited) (in thousands)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Product revenue:Instruments5,1305,2159,60011,861
Product revenue:Consumables9,38510,45820,36918,593
Product revenue:Total product revenue14,51515,67329,96930,454
Product revenue:Services and other revenue5,5896,08911,28111,530
Product revenue:Total revenue20,10421,76241,25041,984

Income Statement

Three Months Ended June 30, — ITEMIZED RECONCILIATION OF GROSS PROFIT TO NON-GAAP GROSS PROFIT AND MARGIN PERCENTAGE

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Gross profit10,53510,62821,84321,677
Depreciation and amortization338554684817
Stock-based compensation expense453402994644
Loss on disposal of property and equipment187187
Non-GAAP gross profit11,32611,77123,52123,325
Gross margin percentage52.4%48.853.0%51.6
Depreciation and amortization1.6%2.61.6%2
Stock-based compensation expense2.3%1.82.4%1.6
Loss on disposal of property and equipment0.90.4
Non-GAAP gross margin percentage56.3%54.157.0%55.6

Balance Sheet

December 31, — (Unaudited) (in thousands)

June 30, – 2026December 31, – 2025
Current assets:Cash and cash equivalents270,026120,863
Current assets:Short-term investments206,69366,712
Current assets:Accounts receivable, net15,74713,431
Current assets:Inventory17,10319,981
Current assets:Prepaid expenses and other current assets7,2984,871
Current assets:Current assets held for sale228,406
Current assets:Total current assets516,867454,264
Current assets:Property and equipment, net15,30019,275
Current assets:Operating lease right-of-use asset, net24,24626,732
Current assets:Other non-current assets3,2613,154
Current assets:Long-term investments67,28025,701
Current assets:Deferred tax asset, non-current26438,628
Current assets:Total assets627,218567,754
Current liabilities:Accounts payable9,5545,407
Current liabilities:Accrued liabilities29,60829,783
Current liabilities:Operating lease liabilities, current5,6215,490
Current liabilities:Deferred revenue, current9,14438,949
Current liabilities:Deferred grant income, current2,8753,046
Current liabilities:Current liabilities held for sale25,633
Current liabilities:Total current liabilities56,802108,308

Cash Flow

Six Months Ended June 30, — (Unaudited) (in thousands)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Operating activitiesNet income (loss)100,310-59,492
Operating activitiesGain on sale of business-172,289
Operating activitiesIndemnification-related loss4,212
Operating activitiesStock-based compensation expense12,87415,396
Operating activitiesAmortization of acquired intangible assets1,715
Operating activitiesDepreciation and amortization2,6816,450
Operating activitiesAccretion of discount on investments, net-1,839-1,571
Operating activitiesRealized gain on equity investments-1,187
Operating activitiesUnrealized loss on equity investments2,542
Operating activitiesNon-cash lease expense2,6002,865
Operating activitiesProvision for excess and obsolete inventory1,7701,360
Operating activitiesChange in fair value of warrants-232
Operating activitiesChange in fair value of contingent consideration-3,400
Operating activitiesOther non-cash items46477
Operating activitiesChanges in assets and liabilities, net-8,628-14,519
Operating activitiesNet cash used in operating activities-56,908-50,951
Investing activitiesCash received for sale of business, net388,214
Investing activitiesPurchases of short-term investments-127,208-50,929
Investing activitiesPurchases of long-term investments-109,845
Investing activitiesPurchases of marketable equity securities-839
Investing activitiesProceeds from sales of equity investments3,090
Investing activitiesProceeds from sales and maturities of investments53,000100,000
Investing activitiesPurchases of property and equipment-914-6,941
Investing activitiesNet cash provided by investing activities205,49842,130
Financing activitiesProceeds from ESPP stock issuance120308
Financing activitiesPayments for taxes related to net share settlement of equity awards and other-376-246
Financing activitiesProceeds from exercise of stock options78
Financing activitiesNet cash provided by (used in) financing activities-17862
Financing activitiesEffect of foreign exchange rate fluctuations on cash and cash equivalents4091,145
Financing activitiesNet (decrease) increase in cash, cash equivalents and restricted cash148,821-7,614
Financing activitiesCash, cash equivalents and restricted cash at beginning of period123,296168,818
Financing activitiesCash, cash equivalents and restricted cash at end of period272,117161,204
Cash, cash equivalents, and restricted cash consists of:Cash and cash equivalents270,026158,617
Cash, cash equivalents, and restricted cash consists of:Restricted cash2,0912,587
Cash, cash equivalents, and restricted cash consists of:Total cash, cash equivalents and restricted cash272,117161,204
Full release

Forward-Looking Statements... (truncated)the closing of that transaction; operational and strategic plans; deployment of capital; and market and growth opportunity and potential. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, risks that the proposed merger with Treeline Biosciences may not be completed on the anticipated timeline or at all, including risks related to obtaining stockholder approval and satisfying other closing conditions; risks related to the proposed sale of the Mass Cytometry business, including risks that the transaction may not close on the anticipated timeline or at all; the potential that the expected benefits and opportunities of the proposed merger may not be realized or may take longer to realize than expected; possible integration, restructuring and transition-related disruption resulting from the proposed transactions, including through the loss of customers, suppliers, and employees and adverse impacts on the Company’s development activities and results of operation; management distraction and reduced operating performance during the pendency of the proposed transactions; risks that internal and external costs required for ongoing and planned activities may be higher than expected, which may cause the Company to use cash more quickly than it expects or change or curtail some of the Company’s plans, or both; risks that the Company’s expectations as to expenses, cash usage, and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; changes in the Company’s business or external market conditions; existing and potential future NIH funding pressures; the effect from existing and potential future U.S. export controls and tariffs; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, the Company’s products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; continued or sustained budgetary, inflationary, or recessionary pressures; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; uncertainties relating to the Company’s research and development activities, and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. For information regarding other related risks, see the “Risk Factors” section of the Company’s annual report on Form 10-K, for the year ended December 31, 2025, filed with the SEC on March 16, 2026, the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2026, to be filed with the SEC, the Company’s registration statement on Form S-4, filed with the SEC on July 20, 2026 in connection with the proposed merger with Treeline Biosciences, and in the Company’s other filings with the SEC. These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements except as may be required by law.

About Standard BioTools Inc.

Standard BioTools, Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team. The Company's established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/terms-and-conditions/.

Patent and License Information: standardbio.com/legal/notices.

Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2026 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Investor Contact: ir@standardbio.com

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Standard Biotools earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.